Saliva as a Reliable and Non-Invasive Sample

for Detecting Influenza A in Severe Acute Respiratory Infection Cases

Running title: Saliva as a Reliable Sample for Detecting Influenza A in SARI

Word count of abstract: 204 words (250 word limit)

Word count of body: 2910 words (3000 word limit)

Author names:

Junko S. Takeuchi[1], Nobuaki Matsunaga[2*], Ai Tsukada[2], Noriko Iwamoto[3], Noriko

Fuwa[3], Takahiro Ichikawa[4], Yasuyuki Kato[5], Yuka Tomita[6], Hiroki Kitagawa[7], Masaya

Yamato[8], Tetsuji Aoyagi[9], Hideharu Hagiya[10], Ryota Hase[11], Shuji Hatakeyama[12], Tohru

Inaba[13], Koichi Izumikawa[14], Yoshio Takesue[15], Moto Kimura[1], Norio Ohmagari[3]

Affiliations:

[1] Department of Academic-Industrial Partnerships Promotion, Center for Clinical

Sciences, Japan Institute for Health Security, Tokyo 162-8655, Japan

[2] AMR Clinical Reference Center, Japan Institute for Health Security, Tokyo 162-8655,

Japan

[3] Disease Control and Prevention Center, Japan Institute for Health Security, Tokyo

162-8655, Japan

[4] Department of Infectious Diseases, Sapporo City General Hospital, Hokkaido,

060-8604, Japan

[5] Department of Infectious Diseases, IUHW Narita Hospital, Chiba 286-8520, Japan

[6] Department of Infectious Diseases, Japanese Red Cross Aichi Medical Center Nagoya

Daini Hospital, Aichi 466-8650, Japan

[7] Department of Infectious Diseases, Hiroshima University Hospital, Hiroshima

734-8551, Japan

[8] Department of General Internal Medicine and Infectious Diseases, Rinku General

Medical Center, Osaka 598-8577, Japan

[9] Department of Clinical Infectious Diseases, Tohoku University Graduate School of

Medicine, Miyagi, 980-8575, Japan

[10] Department of Infectious Diseases, Okayama University Hospital, Okayama 700-8558,

Japan

[11] Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Chiba

286-8523, Japan

[12] Division of Infectious Diseases, Jichi Medical University Hospital, Tochigi 329-0498,

Japan

[13] Department of Infection Control & Laboratory Medicine, Kyoto Prefectural

University of Medicine, Kyoto 602-8566, Japan

[14] Department of Infectious Diseases, Nagasaki University Graduate School of

Biomedical Sciences, Nagasaki 852-8501, Japan

[15] Infectious Disease Department, Chita Peninsula General Medical Organization, Chita

Peninsula Rinku Hospital, Aichi 479-8510, Japan

*Corresponding Author

Nobuaki Matsunaga, MD, MPH, PhD

AMR Clinical Reference Center, Japan Institute for Health Security.

1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, JAPAN

TEL: +81-3-6228-0062

E-mail: matsunaga.no@jihs.go.jp

Abstract

Nasopharyngeal swab sampling can be limited by critical factors, such as dependence on medical staff, invasiveness, nosocomial transmission, and occupational exposure risk. This study aimed to investigate whether saliva and nasal vestibular swabs are suitable non-invasive alternatives to nasopharyngeal swabs for influenza A detection in severe acute respiratory infections (SARIs). Saliva samples demonstrated a higher sensitivity (87.5%) than did nasal vestibular swabs (31.3%) in RT-qPCR. While nasal vestibular swabs showed inconsistent results, saliva samples consistently tested positive, particularly within 7 days of symptom onset (100% positive agreement). In addition, diagnosis with RT-qPCR is often delayed because it requires trained laboratory technicians and facilities with appropriate laboratory settings. Therefore, the GenPad®, a rapid diagnostic device, was evaluated and showed promising performance (92.9%) compared with the efficiency of RT-qPCR. Factors such as the location of infection (upper vs. lower respiratory tract infections), sample collection timing, pre-collection instructions, and nucleic acid extraction possibly contributed to the detection efficiency. Despite the small sample size (n=16) and lack of influenza-negative controls, our findings support saliva as a viable self-collected diagnostic sample for influenza A diagnosis and surveillance programs. Non-invasive sampling mitigates discomfort, minimizes infection risk for healthcare workers, and improves testing capacity, particularly under frequent staff shortages during pandemics.

Keywords

Highlights

- We aimed to propose alternatives to nasopharyngeal swab sampling

79　● Saliva samples demonstrated a high sensitivity in RT-qPCR

80　● Nasal vestibular swab samples may pose a risk of sampling bias

81　● The GenPad® demonstrated performance comparable to that of the RT-qPCR

82　method

1. Introduction

The Coronavirus Disease 2019 (COVID-19) pandemic has prompted a more comprehensive surveillance of acute respiratory infections (ARIs), including COVID-19, Respiratory Syncytial Virus (RSV) infection, and influenza, worldwide [1]. Countries use surveillance systems such as the Respiratory Virus Hospitalization Surveillance Network (RESP-NET; the United States) [2], the Severe Acute Respiratory Infection Watch (SARI Watch; the United Kingdom) [3], and the European Respiratory Virus Surveillance Summary (ERVISS; European Union) [4]. In Japan, clinical information and specimens derived from severe acute respiratory infections (SARIs) have been added to the Infectious Disease Clinical Research Network With National Repository (iCROWN, the successor to REBIND) since September 2024 [5]. Furthermore, on April 7, 2025, ARI has been designated a "Category V Infectious Diseases" under Japan's Infectious Disease Control Law [6] and is subjected to sentinel surveillance.

As a SARI/ARI, influenza requires early diagnosis to appropriately guide antiviral therapy and patient isolation for effective disease control [7,8]. Antiviral treatment is most effective when initiated within 48 h of symptom onset, helping to reduce the likelihood of hospitalization or the need for critical care, as well as to prevent further transmission within the community. However, at the beginning of the COVID-19 pandemic, two major challenges in diagnosing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were highlighted. First, sample collection relied exclusively on healthcare workers. Second, reverse transcription real-time quantitative PCR (RT-qPCR)-based diagnosis was delayed due to the need for specialized personnel and facilities. In response, self-sampling and point-of-care testing (POCT) methods for molecular diagnosis were developed [9].

Although nasopharyngeal swab sampling remains the gold standard for influenza diagnosis, it requires medical personnel and can be uncomfortable, especially for children. Amid pandemics, staff shortages and the risk of aerosol generation during

nasopharyngeal swab sampling further complicate this approach. Less-invasive, self-collectable methods such as saliva or nasal vestibular (anterior nasal cavity) swab sampling offer a practical alternative. These simpler methods may also increase participation rates in clinical studies and surveillance programs. Thanks to the high sensitivity of RT-qPCR, detection rates across different sample types in influenza virus may be comparable [10]. Multiple studies on influenza detection have reported high concordance rates (93%–100%) between saliva and nasopharyngeal samples [11-19]; however, studies comparing saliva and nasal swab samples are limited [13,20]. Some studies have suggested that saliva is less effective than nasopharyngeal [14] or nasal [13,20] swabs for detecting influenza A. These inconsistencies may result from differences in viral strains, symptom severity, sampling methods, detection techniques, or timing of sample collection.

Historically, viral cultures were the gold standard for influenza detection; however, the process takes up to 7 days [21]. RT-qPCR is now the common approach because of its speed (typically 2–3 h, including RNA extraction) and high sensitivity; however, it requires specialized facilities and a stable power supply, limiting its application in smaller or rural clinical setups and in urgent settings [22]. To address these challenges, the GenPad® (MIRAI GENOMICS, Kanagawa, Japan) represents a promising alternative. It utilizes isothermal nucleic acid amplification based on SmartAmp (a Smart Amplification Process) and fluorescence detection [23,24], offering a portable, battery-operated solution with results within 50 min. However, few studies have examined its performance using clinical samples.

This study addresses the two key questions in SARI diagnostics: (i) can saliva or nasal vestibular swab samples serve as suitable alternatives to nasopharyngeal swab samples, and (ii) can the GenPad® provide a reliable option for influenza using saliva samples.

2. Materials and methods

2.1. Ethics statement

This study was approved by the Ethics Review Committee of the National Center for Global Health and Medicine, Japan (NCGM-S-004948).

2.2. Study participants

We recruited inpatients who met certain criteria at the time of admission in Japan. The case-cohort criteria for SARI were:

i. All of A–C: (A) Respiratory pathogens were detected or strongly suspected. (B) Airway symptoms, such as cough. (C) At the time of admission, the patient was not in a care facility, undergoing tracheotomy, or having confirmed significant dysphagia.

ii. One or more of D–F: (D) Chest imaging showed infiltrates. (E) SpO2 was ≤94% under room air conditions. (F) New oxygen therapy, invasive mechanical ventilation, or non-invasive mechanical ventilation were introduced.

All patients gave informed consent for participation in the prospective observation study.

Sixteen patients classified as having SARIs and diagnosed with influenza participated in this study. Patients were diagnosed at day 0–4 (median: 1) after onset at each medical facility using one of the following methods with nasopharyngeal swab samples: Film Array test, Rapid Test kit, or antigen test (the day of onset was designated as day 0). There were 13 (81.25%) male participants with a median age of 67.5 years. All clinical samples were collected 1–9 (median: 3.5) days after symptom onset. Paired samples (saliva and nasal vestibular samples) were collected from each patient on the same day. The nasal vestibular samples were collected using a swab and preserved in 3 mL of Universal Transport Medium (FLOQSwabs® and UTM®, 307C; Copan, Brescia, Italy). Saliva samples were collected in sterile tubes without

preservative medium using a saliva collector (SP1-RO0003-56, AXIS Inc., Ibaraki, Japan). The participants avoided gargling, brushing their teeth, or eating within 30 min before sample collection. All residual samples were stored at −20 or −80 °C until use.

2.3. *Nucleic acid extraction*

Each saliva sample (150 µL) was diluted with an equal volume of phosphate-buffered saline without calcium and magnesium [PBS(-)], vigorously mixed, and spun-down. Nucleic acid (60 µL) was extracted from 200 µL of sample, either saliva [diluted two-fold with PBS(-)] or nasal vestibular swab suspended in 3 mL of UTM, using a KingFisher APEX System (Thermo Fisher Scientific, Waltham, MA, USA) and the MagMAX Prime Viral/Pathogen NA Isolation Kit (A58145; Thermo Fisher Scientific), with 60% ethanol used as the second wash buffer.

2.4. *Reverse transcription real-time quantitative polymerase chain reaction*

RT-qPCR was performed according to the Influenza Diagnostic Manual (5th Edition, August 2023) published by the National Institute of Infectious Diseases (NIID), Japan [25]. Briefly, RT-qPCR was performed on a QuantStudio®3 real-time PCR system (Thermo Fisher Scientific) using AgPath-IDTM One-Step RT-PCR Reagents (AM1005; Thermo Fisher Scientific) with the following primer/probe sets: the influenza A set comprised [MP-39-67For (5'-CCMAGGTCGAAACGTAYGTTCTCTCTATC-3'), MP-183-153Rev (5'-TGACAGRATYGGTCTTGTCTTTAGCCAYTCCA-3'), and MP-96-75ProbeAs (5'-FAM-ATYTCGGCTTTGAGGGGGCCTG-MGB-3')]; the influenza B set consisted of [NIID-TypeB TMPrimer-F1 (5'-GGAGCAACCAATGCCAC-3', NIID-TypeB TMPrimer-R1 (5'-GTKTAGGCGGTCTTGACCAG-3'), and NIID-TypeB Probe2 (5'-FAM-ATAAACTTYGAAGCAGGAAT-MGB-3')]. Subsequently, 5 µL of the extracted nucleic acid was used as the template in 25 µL of an RT-qPCR reaction

mixture using the following conditions: 50 °C for 10 min, 95 °C for 10 min, followed

by 45 cycles of 95 °C for 15 sec, 56 °C for 30 sec, and 72 °C for 15 sec. The data was

analyzed using QuantStudio^{TM} Design & Analysis Software v1.5.2. The test was

considered successful when amplification and no-amplification curves were confirmed

in the positive and negative (nuclease-free water) controls, respectively. A sample was

considered positive when the amplification curve increased. The positive RNA controls

were kindly provided by the NIID [for influenza A: (A/Wisconsin/67/2022, AH1 pdm

S2 +hCK1); for influenza B: (B/Austria/1359417/2021, B Victoria S1C4/ C2 +HCK1)].

2.5. *GenPad system*

The GenPad® Smart CoV2/FluA/FluB Research Use Only kit (RR072; MIRAI

GENOMICS) was used on a GenPad® device according to the manufacturer's protocol

with minor modifications. In contrast to using a swab-collected saliva sample, as

instructed in the kit, 150 µL of saliva sample was used. Briefly, a saliva sample (150

µL) was added to a tube containing a swab suspension buffer (SSB; 2.0 mL). After

inversion mixing, a nozzle cap was attached to the tube, and the extracted mixture was

added to the Sample Loading Level of the GenPad Smart test cartridge. When the filter

of the nozzle cap became clogged due to the viscosity of saliva sample, it was replaced

with a new cap.

2.6. *Statistical analysis*

Positive and negative agreement rates were obtained using epi.tests of the epiR package

v.2.0.78 in R 4.3.2 (R Foundation for statistical Computing, Vienna, Austria), with a

95% confidence interval (CI) calculated using the Wilson method [26]. To assess

differences in Threshold Cycle (Ct) values between saliva and nasal vestibular swabs,

Student's t-test for paired samples was performed using R 4.3.2. The correlation and

p-value between RT-qPCR Ct values and GenPad® Threshold Time (Tt) values were

calculated through Spearman's rank correlation using R 4.3.2.

3. Results

We tested paired saliva and nasal vestibular samples collected on the same day from 16

patients classified as having SARI and diagnosed with influenza between December

2024 and March 2025 in Japan. All patients, except for case No. 8, had either no history

of influenza vaccination or an unknown vaccination status. RT-qPCR revealed that all

analyzed samples contained influenza A. Although the RT-qPCR in this study was

qualitative and lacked a calibration curve, all samples were tested on the same plate,

except for No. 16, allowing Ct-based comparisons. Although No. 16 was tested

separately, its positive control Ct value (31.4) was equivalent to the other assay (31.6),

so it was included in the analysis.

We first compared the diagnostic results obtained from nasopharyngeal swabs

(collected at medical facilities) with the RT-qPCR of the saliva and nasal vestibular

samples. As this study only included influenza-positive cases, a positive agreement rate

could be calculated; 87.5% (14 of 16) for saliva and 31.3% (5 of 16) for nasal vestibular

swab samples.

Subsequently, we compared the RT-qPCR results of the saliva and nasal

vestibular samples (Figure 1). The positive, negative, and total agreement rates were

35.7% (95% CI: 16.3%–61.2%), 100% (34.2%–100%), and 43.8% (23.1%–66.8%),

respectively (Table 1). Saliva samples showed significantly[*] greater detection

sensitivity than nasal vestibular samples. [*]When there was no detectable amplification,

the Ct values were treated as missing (*NA*), and no significant difference was found

(p=0.16) owing to insufficient sample size (n=5); however, when these values were

replaced with 40, the difference became significant (p=0.0015), possibly owing to the

increased sample size (n=16). When saliva Ct values were ≥37, those of nasal vestibular

samples were undetectable (n=6), whereas nasal vestibular samples were also detectable

when saliva Ct values were ≤30 (n=3).

Next, we evaluated the relationship between clinical information and the Ct

values of the RT-qPCR. Prior to sample collection, peramivir was administered to Nos.

1–7 and 14; oseltamivir to Nos. 8, 13, and 15; and no antiviral treatment was given to

Nos. 9–12 and 16. Although Nos. 7 and 15 (both of whom had received antiviral

treatment) tested negative under RT-qPCR, the fact that other treated patients yielded

positive results suggested that antiviral treatment alone does not fully account for the

variability in detection sensitivity. In contrast, the number of days from onset to sample

collection appears to be more relevant: Nos. 7 and 15 were collected on day 8 or 9

post-onset, when viral loads had likely been reduced, possibly explaining the negative

results (Figure 2). Sample No. 14 was collected on day 8 and had the second-lowest Ct

value (second-highest viral load). However, this patient was immunosuppressed due to

complications following hematopoietic stem cell transplantation and was receiving

multiple immunosuppressive therapies, suggesting prolonged viral persistence.

Similarly, we compared the GenPad® and RT-qPCR using saliva samples

(Figure 3). The positive, negative, and total agreement rates were 92.9%

(68.5%–98.7%), 100% (34.2%–100%), and 93.8 (71.7%–98.9%), respectively (Table 2).

One discordant sample No. 12 yielded a Ct value (39.5) using RT-qPCR but was not

detected by the GenPad®, suggesting that the viral load was near or below the detection

limit of the GenPad®. Although Spearman's rank correlation coefficient between Tt/Ct

values of the GenPad® and RT-qPCR was moderately high (r=0.522), it did not reach

statistical significance (p=0.067). The GenPad® Smart CoV2/FluA/FluB kit detects

Influenza A, B and SARS-CoV-2; however, only influenza A was detected in this study,

consistent with RT-qPCR (although the detection of SARS-CoV-2 was not included in

the RT-qPCR).

4.   Discussion

RT-qPCR showed that saliva samples were more sensitive than nasal vestibular swabs

for influenza A detection in SARI cases. This is inconsistent with the results of Goff et

al., which demonstrated poor sensitivity of saliva compared to nasal swabs [13] and

several causes could be considered. First, our SARI cases likely included viral

pneumonia (lower respiratory tract infections [LRTIs]), whereas, Goff et al. [13]

reported non-severe seasonal influenza cases (upper respiratory tract infections

[URTIs]). These clinical differences may have involved differences in viral load

distribution within the respiratory tract, potentially affecting the sensitivity of sample

types. Second, our study followed strict pre-collection conditions, asking the

participants to avoid gargling, brushing their teeth, or eating within 30 min before

sample collection based on the guidelines of the Ministry of Health, Labour and Welfare.

These actions interfere with viral detection in saliva samples, according to studies on

SARS-CoV-2 [27,28], possibly because the impurities in saliva samples may affect PCR

efficiency [29]. In contrast, in the study by Goff et al. [13] conducted before the

COVID-19 pandemic, these conditions were not established for saliva collection, which

may have affected virus detection. However, even when similar pre-collection

conditions are applied, other factors may still influence detection sensitivity. For

example, another study by Norizuki et al. [30], who tested asymptomatic travelers for

SARS-CoV-2 and implemented similar pre-collection conditions for saliva sampling,

reported low detection rates in saliva samples. Norizuki et al. [30] noted that the

participants self-collected samples without supervision at busy airport quarantine

stations, which may have affected their results. Thus, supervised saliva collection under

conditions that meet pre-collection requirements may be preferable. Next, we extracted

nucleic acids from the saliva samples to effectively remove impurities, ensuring that

their impact on the results was minimized. In contrast, Goff et al. [13] used several rapid

diagnostic kits, a condition where the substances in the saliva might have interfered

with the outcomes.

The lower and variable sensitivity of nasal vestibular swabs may be related to

the location of respiratory symptoms (presence of nasal discharge, URTIs vs. LRTIs),

age group (children or adults), sampling techniques (rubbed vigorously or lightly, swab

suspension ratio), or collection area (anterior or posterior of the nasal cavity). These

results indicate that nasal vestibular swab samples may pose a risk of sampling bias.

Additionally, Branche et al. reported that RT-qPCR revealed higher mean viral loads in

sputum than in nasal or throat swabs for influenza A [31]. Therefore, sputum should be

considered as a representative sample for influenza detection.

Most healthy volunteers ceased shedding influenza virus by day 6 or 7 [32,33],

though shedding may last longer in children or immunocompromised patients [34,35].

In our study, all saliva samples collected at ≤7 days of onset tested positive, with

saliva-based RT-qPCR showing 100% positive agreement with nasopharyngeal

diagnostics (Figure 2). Although pediatric cases were not included in this study, the only

minor case (aged 15–19, No. 4) tested positive in both saliva and nasal vestibular

samples on day 7. Furthermore, although it is just one case, we confirmed that an

immunosuppressed patient (No. 14) can retain higher levels of the virus for an extended

period, as previously reported [34].

A saliva-based rapid diagnostic kit, the GenPad®, demonstrated relatively

good performance (positive agreement rate 92.9%). This aligns with a previous report

showing a 100% positive concordance rate compared with that of the RT-qPCR

method; however, the result was based on SARS-CoV-2 detection in saliva samples

[36]. Suspension of the saliva samples in SSB containing ethanol and a chaotropic agent

(guanidine thiocyanate), followed by filtration through a glass filter, may effectively

contribute to the removal of impurities and elution of nucleic acids. Notably, 150 μL of

saliva sample was directly treated with SSB in this study despite the kit's protocol

specifying swab-collected saliva; therefore, further evaluation is warranted. The

COVID-19 pandemic highlighted the use of saliva as a sensitive and reliable diagnostic

sample, especially for nucleic acid testing [19,37]. A growing body of evidence supports its use of saliva for detecting other respiratory pathogens including influenza. This may promote the approval of saliva-based diagnostic tests for influenza. Although not assessed in this study, saliva has reportedly shown lower sensitivity in immunochromatographic rapid antigen tests [38].

The strength of this study is the direct comparison of two non-invasive sample types using RT-qPCR and access to detailed clinical data, such as the treatment history and the symptom onset date. However, this study had some limitations. First, we did not evaluate nasopharyngeal swabs simultaneously. Second, the samples were collected 1 to 9 days after the onset of symptoms, and antiviral therapy had been initiated in 11 out of 16 cases. These factors (a prolonged interval between onset and testing or prior treatment) may have reduced viral loads in both saliva and nasal vestibular swab samples, potentially lowering overall detection sensitivity. Third, the samples were small-scale (n=16) and biased toward those obtained in SARI cases in Japan, preventing the generalizability of the results to a larger population or other settings. Fourth, because we did not include a control group of influenza-negative patients, we could not evaluate the negative agreement rate. Finally, while we confirmed the virus detection from saliva samples, further evaluation of viral characteristics are warranted, particularly to assess whether viable viruses can be isolated from saliva, as described in SARS-CoV-2 studies [39,40].

We demonstrated that the use of saliva, but not nasal vestibular swabs, is a potential non-invasive alternative to nasopharyngeal swabs for influenza A virus detection particularly within 7 days of symptom onset. Additionally, the GenPad® provides comparable results to RT-qPCR. These methods may reduce the burden on patients and healthcare settings, mitigate nosocomial infections, and increase participation rates when applied for clinical studies and surveillance purposes.

Glossary

SARI, severe acute respiratory infection; ARI, acute respiratory infection; COVID-19, coronavirus disease 2019; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RT-qPCR, reverse transcription real-time quantitative PCR; POCT, point-of-care testing; NIID, National Institute of Infectious Diseases; PBS, phosphate-buffered saline; CI, confidence interval; Threshold Cycle, Ct; Threshold Time, Tt; URTIs, upper respiratory tract infections; LRTIs, lower respiratory tract infections

Data availability statement

The data that support the findings of this study, excluding those subjects to privacy or ethical restrictions, are available from the corresponding author upon reasonable request.

Declaration of competing interests

The authors have no conflicts of interest to disclose.

Funding sources

This research was supported by AMED under Grant Number JP23fk0108600.

Author contributions

Conceptualization, Funding acquisition: NM.

Methodology: NM, NI, NF, Takahiro I, YK, Yuka T, HK, MY, TA, HH, RH, SH, Tohru I, KI, and Yoshio T.

Resources: NI, NF, Takahiro I, YK, Yuka T, HK, and MY.

Software, Formal analysis, Investigation, Visualization, Writing - Original Draft: JST.

Validation, Data Curation, Project administration: AT and NM.

Supervision: MK and NO.

Writing - Review & Editing: all authors

Acknowledgements

We are grateful to the patients who contributed to this study. We thank clinical staff of

the National Center for Global Health and Medicine, Japan, Dr. Atsushi Nagasaka[4], Dr.

Saho Takaya[5], Ms. Masako Shikami[5], Dr. Retsu Fujita[5], Dr. Hisashi Wakayama[6], Dr.

Naohiko Murata[6], Dr. Hiroki Ohge[7], and Dr. Norifumi Shigemoto[7]for providing the

clinical samples and the valuable suggestions on the manuscript; Dr. Chiho Kitamura[9],

Dr. Asami Nakayama [9], Dr. Shinnosuke Fukushima[10], Dr. Kenta Nakamoto[10], Dr.

Haruhiko Ishioka[12], Dr. Takaaki Nakaya[13], Mr. Yukiji Yamada[13], Dr. Hiroshi Ikai[13], Mr.

Takeo Okashita[13], and Dr. Masato Tashiro[14] for insightful comment on the manuscript;

Dr. Tadaki Suzuki[16] and Dr. Sho Miyamoto[16] for providing the positive RNA control; Dr.

Nobuhiro Takemae[16] for valuable advice on the RT-qPCR protocol; and Ms. Azusa

Kamikawa[1], Dr. Sakino Takayanagi-Nishisako[1], Ms. Emiko Hatano[1], Dr. Kento Fukano[1],

and Ms. Ryoko Tamura[1] for their experimental support. (The affiliation identifiers listed

here are the same as those listed in the Author section. In addition, affiliation 16

corresponds to the National Institute of Infectious Diseases, Japan.)

Declaration of generative AI and AI-assisted technologies in the writing process

No generative AI or AI-assisted technologies were used in the writing process of this

manuscript.

Figure caption

Figure 1. Comparison of Ct values obtained via reverse transcription quantitative PCR

(RT-qPCR) among different sample types

Blue and pink circles indicate Ct values of saliva and nasal vestibular samples,

respectively.

N.D.; not detected (There was no detectable amplification).

Figure 2. Comparison of RT-qPCR Ct values with time from symptom onset to sample

collection

Days since symptom onset are shown on the x-axis, and Ct values are on the y-axis.

Blue and pink circles represent saliva and nasal vestibular samples, respectively.

Figure 3. Correlation of Tt/Ct values between the GenPad and RT-qPCR methods

Blue circles indicate Tt/Ct values of saliva samples, respectively.

N.D.; not detected (There was no detectable amplification).

References

[1]   Matsunaga N, Ohmagari N. Surveillance of Severe Acute Respiratory Infections
(SARI) in Europe, the United States, and Japan. (Japanese). Infectious Agents
Surveillance Report (IASR) 2024;45:200-1.

[2]   CDC. Respiratory Virus Hospitalization Surveillance Network （RESP-NET）,
https://www.cdc.gov/resp-net/dashboard/ [accessed April 10, 2025].

[3]   UK Health Security Agency. The severe acute respiratory infection (SARI)
Watch   surveillance   system,
https://www.gov.uk/government/publications/sources-of-surveillance-data-for-in
fluenza-covid-19-and-other-respiratory-viruses/data-quality-report-national-flu-a
nd-covid-19-surveillance-report#secondary-care-surveillance-sari-watch
[accessed April 10, 2025].

[4]   The European Respiratory Virus Surveillance Summary (ERVISS)
https://erviss.org/ [accessed April 10, 2025].

[5]   iCROWN, https://nwp.ncgm.go.jp/index.html [accessed May 12, 2025].

[6]   Act on the Prevention of Infectious Diseases and Medical Care for Patients with
Infectious Diseases, https://www.japaneselawtranslation.go.jp/ja/laws/view/4822
[accessed May 10, 2025].

[7]   Louie JK, Acosta M, Jamieson DJ, Honein MA, California Pandemic Working G.
Severe 2009 H1N1 influenza in pregnant and postpartum women in California.

439   N Engl J Med 2010;362:27-35. https://doi.org/10.1056/NEJMoa0910444.

440 [8] Glezen WP. Clinical practice. Prevention and treatment of seasonal influenza. N
441   Engl J Med 2008;359:2579-85. https://doi.org/10.1056/NEJMcp0807498.

442 [9] Jayamohan H, Lambert CJ, Sant HJ, Jafek A, Patel D, Feng H, et al.
443   SARS-CoV-2 pandemic: a review of molecular diagnostic tools including
444   sample collection and commercial response with associated advantages and
445   limitations. Anal Bioanal Chem 2021;413:49-71.
446   https://doi.org/10.1007/s00216-020-02958-1.

447 [10] Spencer S, Thompson MG, Flannery B, Fry A. Comparison of Respiratory
448   Specimen Collection Methods for Detection of Influenza Virus Infection by
449   Reverse Transcription-PCR: a Literature Review. J Clin Microbiol 2019;57.
450   https://doi.org/10.1128/JCM.00027-19.

451 [11] Bilder L, Machtei EE, Shenhar Y, Kra-Oz Z, Basis F. Salivary detection of
452   H1N1 virus: a clinical feasibility investigation. J Dent Res 2011;90:1136-9.
453   https://doi.org/10.1177/0022034511413283.

454 [12] Galar A, Catalan P, Vesperinas L, Miguens I, Munoz I, Garcia-Espona A, et al.
455   Use of Saliva Swab for Detection of Influenza Virus in Patients Admitted to an
456   Emergency Department. Microbiol Spectr 2021;9:e0033621.
457   https://doi.org/10.1128/Spectrum.00336-21.

458 [13] Goff J, Rowe A, Brownstein JS, Chunara R. Surveillance of Acute Respiratory
459   Infections Using Community-Submitted Symptoms and Specimens for
460   Molecular Diagnostic Testing. PLoS Curr 2015;7.
461   https://doi.org/10.1371/currents.outbreaks.0371243baa7f3810ba1279e30b96d3b
462   6.

463 [14] Kim YG, Yun SG, Kim MY, Park K, Cho CH, Yoon SY, et al. Comparison
464   between Saliva and Nasopharyngeal Swab Specimens for Detection of
465   Respiratory Viruses by Multiplex Reverse Transcription-PCR. J Clin Microbiol
466   2017;55:226-33. https://doi.org/10.1128/JCM.01704-16.

467 [15] Sueki A, Matsuda K, Yamaguchi A, Uehara M, Sugano M, Uehara T, et al.
468   Evaluation of saliva as diagnostic materials for influenza virus infection by
469   PCR-based assays. Clin Chim Acta 2016;453:71-4.
470   https://doi.org/10.1016/j.cca.2015.12.006.

471 [16] To KK, Lu L, Yip CC, Poon RW, Fung AM, Cheng A, et al. Additional
472   molecular testing of saliva specimens improves the detection of respiratory
473   viruses. Emerg Microbes Infect 2017;6:e49.
474   https://doi.org/10.1038/emi.2017.35.

475   [17]   To KKW, Yip CCY, Lai CYW, Wong CKH, Ho DTY, Pang PKP, et al. Saliva as
476   a diagnostic specimen for testing respiratory virus by a point-of-care molecular
477   assay: a diagnostic validity study. Clin Microbiol Infect 2019;25:372-8.
478   https://doi.org/10.1016/j.cmi.2018.06.009.

479   [18]   Yoon J, Yun SG, Nam J, Choi SH, Lim CS. The use of saliva specimens for
480   detection of influenza A and B viruses by rapid influenza diagnostic tests. J Virol
481   Methods 2017;243:15-9. https://doi.org/10.1016/j.jviromet.2017.01.013.

482   [19]   Laxton CS, Peno C, Hahn AM, Allicock OM, Perniciaro S, Wyllie AL. The
483   potential of saliva as an accessible and sensitive sample type for the detection of
484   respiratory pathogens and host immunity. Lancet Microbe 2023;4:e837-e50.
485   https://doi.org/10.1016/S2666-5247(23)00135-0.

486   [20]   Jung EJ, Lee SK, Shin SH, Kim JS, Woo H, Cho EJ, et al. Comparison of Nasal
487   Swabs, Nasopharyngeal Swabs, and Saliva Samples for the Detection of
488   SARS-CoV-2 and other Respiratory Virus Infections. Ann Lab Med
489   2023;43:434-42. https://doi.org/10.3343/alm.2023.43.5.434.

490   [21]   Agoritsas K, Mack K, Bonsu BK, Goodman D, Salamon D, Marcon MJ.
491   Evaluation of the Quidel QuickVue test for detection of influenza A and B
492   viruses in the pediatric emergency medicine setting by use of three specimen
493   collection methods. J Clin Microbiol 2006;44:2638-41.
494   https://doi.org/10.1128/JCM.02644-05.

495   [22]   Soroka M, Wasowicz B, Rymaszewska A. Loop-Mediated Isothermal
496   Amplification (LAMP): The Better Sibling of PCR? Cells 2021;10.
497   https://doi.org/10.3390/cells10081931.

498   [23]   Asai N, Nakamura A, Sakanashi D, Koita I, Ohashi W, Kawamoto Y, et al.
499   Comparative study of SmartAmp assay and reverse transcription-polymerase
500   chain reaction by saliva specimen for the diagnosing COVID-19. J Infect
501   Chemother 2022;28:120-3. https://doi.org/10.1016/j.jiac.2021.09.011.

502   [24]   Nagasawa S, Mori A, Hirata Y, Motomura A, Ishii N, Okaba K, et al. SmartAmp
503   method can rapidly detect SARS-CoV-2 in dead bodies. Forensic Sci Int
504   2022;331:111168. https://doi.org/10.1016/j.forsciint.2021.111168.

505   [25]   The National Institute of Infectious Diseases (NIID), Japan. The Influenza
506   Diagnostic Manual, 5th edition (August 2023),
507   https://id-info.jihs.go.jp/relevant/manual/010/influenza20230829.pdf].

508   [26]   epiR: Tools for the Analysis of Epidemiological Data,
509   https://CRAN.R-project.org/package=epiR].

[27]   Meister TL, Bruggemann Y, Todt D, Conzelmann C, Muller JA, Gross R, et al.

Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory
Syndrome Coronavirus 2. J Infect Dis 2020;222:1289-92.
https://doi.org/10.1093/infdis/jiaa471.

[28] Costa MM, Benoit N, Tissot-Dupont H, Million M, Pradines B, Granjeaud S, et
al. Mouth Washing Impaired SARS-CoV-2 Detection in Saliva. Diagnostics
(Basel) 2021;11. https://doi.org/10.3390/diagnostics11081509.

[29] Alaeddini R. Forensic implications of PCR inhibition--A review. Forensic Sci Int
Genet 2012;6:297-305. https://doi.org/10.1016/j.fsigen.2011.08.006.

[30] Norizuki M, Hachiya M, Motohashi A, Moriya A, Mezaki K, Kimura M, et al.
Effective screening strategies for detection of asymptomatic COVID-19
travelers at airport quarantine stations: Exploratory findings in Japan. Glob
Health Med 2021;3:107-11. https://doi.org/10.35772/ghm.2020.01109.

[31] Branche AR, Walsh EE, Formica MA, Falsey AR. Detection of respiratory
viruses in sputum from adults by use of automated multiplex PCR. J Clin
Microbiol 2014;52:3590-6. https://doi.org/10.1128/JCM.01523-14.

[32] Aoki FY, Boivin G. Influenza virus shedding: excretion patterns and effects of
antiviral treatment. J Clin Virol 2009;44:255-61.
https://doi.org/10.1016/j.jcv.2009.01.010.

[33] Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, et al.
Time lines of infection and disease in human influenza: a review of volunteer
challenge studies. Am J Epidemiol 2008;167:775-85.
https://doi.org/10.1093/aje/kwm375.

[34] Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of
multidrug-resistant influenza A virus in an immunocompromised patient. N Engl
J Med 2003;348:867-8. https://doi.org/10.1056/NEJM200302273480923.

[35] Sato M, Hosoya M, Kato K, Suzuki H. Viral shedding in children with influenza
virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J
2005;24:931-2. https://doi.org/10.1097/01.inf.0000180976.81055.ce.

[36] Miyashita A, Kurosawa T, Yajima T, Yamazaki E. Performance Evaluation of
SARS-CoV-2 RNA Measuring Device GenPad. J Jpn Soc Lab Med
2023;71:684-7.

[37] Oliveira Neto NF, Caixeta RAV, Zerbinati RM, Zarpellon AC, Caetano MW,
Pallos D, et al. The Emergence of Saliva as a Diagnostic and Prognostic Tool for
Viral Infections. Viruses 2024;16. https://doi.org/10.3390/v16111759.

[38] Kok J, Blyth CC, Foo H, Patterson J, Taylor J, McPhie K, et al. Comparison of a
rapid antigen test with nucleic acid testing during cocirculation of pandemic

influenza A/H1N1 2009 and seasonal influenza A/H3N2. J Clin Microbiol 2010;48:290-1. https://doi.org/10.1128/JCM.01465-09.

[39] Yazawa S, Yamazaki E, Saga Y, Itamochi M, Inasaki N, Shimada T, et al. Evaluation of SARS-CoV-2 isolation in cell culture from nasal/nasopharyngeal swabs or saliva specimens of patients with COVID-19. Sci Rep 2023;13:8893. https://doi.org/10.1038/s41598-023-35915-w.

[40] Jeong HW, Kim SM, Kim HS, Kim YI, Kim JH, Cho JY, et al. Viable SARS-CoV-2 in various specimens from COVID-19 patients. Clin Microbiol Infect 2020;26:1520-4. https://doi.org/10.1016/j.cmi.2020.07.020.

Tables

Table 1. Comparison of RT-qPCR using saliva and nasal vestibule samples

RT-qPCR		Nasal vestibule		
		Positive	Negative	Total
	Positive	5	9	14
Saliva	Negative	0	2	2
	Total	**5**	**11**	**16**

Table 2. Comparison of RT-qPCR and GenPad using saliva sample

Saliva		GenPad		
		Positive	Negative	Total
	Positive	13	1	14
RT-qPCR	Negative	0	2	2
	Total	**13**	**3**	**16**

Figure 1.
Ct values by sample type

Figure 2.
Ct values and days from onset to sample collection

Figure 3.
Correlation of Ct values between Genpad and RT-qPCR methods